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OBJECTIVE: Health-related utility is poorly characterised in
stroke patients with limb spasticity. The purpose of this study
was to evaluate health utility in stroke patients with and without
upper and lower limb spasticity. METHODS: Data were
abstracted from the Health Outcomes Data Repository
(HODaR) describing treatment patterns, outcomes and quality
of life following a modiﬁed survey describing 151 patients 
who had experienced a stroke in the last two years. Data were
available describing demographics, the EQ5D and the pres-
ence/absence of self reported limb spasticity. These data were
then linked to routine hospital inpatient data. RESULTS: The
mean age was 72.4 years (56% males). One quarter (26.5%) of
respondents reported no limb spasticity. Of the remainder,
13.9% reported upper limb spasticity only, 11.2% lower limb
spasticity only, and 27.2% a combination of both. Overall, the
mean EQ5Dindex for these patients was 0.55, although patients
reporting no limb spasticity had a higher EQ5Dindex (0.73) com-
pared to those reporting lower limb spasticity (0.36; D = 0.37).
There was a notable difference in utility between those with
upper and lower limb spasticity where patients reporting lower
limb spasticity had lower health utility (0.36 vs. 0.62 respec-
tively; D = 0.26). A similar pattern existed in their duration of
hospital stay with patients experiencing upper and lower limb
spasticity having a mean length of stay of 42.7 days compared
to 29.1 days (lower limb spasticity only) and 20.5 days (upper
limb spasticity only). Patients reporting no limb spasticity had a
mean length of stay of 10.2 days. CONCLUSIONS: The mean
utility estimates obtained from this study show stroke patients
experienced a substantial decrease in quality of life and a further
decrease was recorded in those patients reporting upper and/or
lower limb spasticity. Limb spasticity was also associated with a
substantial increase in hospital length of stay.
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FREQUENCY OF INR TESTING IN MEDICARE BENEFICIARIES
AT HIGH RISK FOR STROKE
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OBJECTIVES: Anticoagulation with warfarin for stroke pre-
vention requires careful management to avoid hemorrhage or
thrombosis. We evaluated the frequency of international nor-
malized ratio (INR) testing in two high-risk Medicare popula-
tions who are likely to receive adjusted-dose warfarin: 1) patients
diagnosed with atrial ﬁbrillation (AF); and 2) patients with a
mechanical heart valve (MHV). METHODS: We analyzed the
2001 Physician Supplier Procedure Summary Master Files
(PSPSMF) database, a 5% sample of procedure-speciﬁc claims
for all physician/supplier services rendered to Medicare beneﬁ-
ciaries. We identiﬁed patients with AF and MHV based on 
any-listed ICD-9-CM diagnosis code of 427.31 and V43.3,
respectively. For each cohort, we searched for claims billed 
under Current Procedural Terminology (CPT) code 85610—
prothrombin testing. We compared prevalence and frequency of
INR testing for each cohort to expected standards of care.
RESULTS: We identiﬁed 141,757 patients with AF and 10,055
patients with MHV, which would yield projected national esti-
mates of 2.8 million and 200,000 patients, respectively. Sixty
percent of AF patients and 43% of MHV patients did not have
a single INR claim. Of AF patients who had at least one INR
test claim, 41% were tested less than 6 times per year, and 59%
were tested 10 or fewer times per year. For MHV patients, 31%
were tested less than 6 times per year, and 47% were tested 10
or fewer times per year. CONCLUSIONS: Medicare claims his-
tories reveal that clinical practice patterns may not adhere to
accepted standards of care for the prevention of stroke in AF and
MHV. Third-party payment policies, provider behavior, lack of
patient awareness, and other factors may contribute to poor
compliance and possible adverse events. Additional studies are
needed to determine the cause of under-compliance in managing
patients at risk for stroke and how Medicare policies may affect
prescribing decisions and patient outcomes.
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CONTINUITY OF CARE IN STROKE PATIENTS UNDER
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OBJECTIVE: To evaluate continuity of care (CoC) and social
capital in stroke patients under rehabilitation in the Mexican
Institute of Social Security (IMSS). METHODS: Cross sectional
study in three IMSS hospitals in Mexico City. Inclusion criteria
were: stroke adult patients surviving a ﬁrst ischaemic event,
consent to participate in the study and capable to answer ques-
tions in an interview. No instruments to measure CoC and social
capital in stroke patients were identiﬁed in our previous litera-
ture review. Three instruments to measure CoC were used:
Mexican one (Constantino), from United States (Chao) and from
Canada (Salmoni). The ﬁrst one is being validated and the other
two have been used and validated in general practice and chronic
patients discharged from hospital to community, respectively.
RESULTS: Forty stroke patients were interviewed, mean age was
68 years, education of 7 years and 87.5% had some chronic
illness (hypertension 58.3%). Sixty seven percent informed that
they were receiving formal rehabilitation and that in 88.2% it
met their needs and expectancies. The Mexican instrument (scale
from 1 to10) found a mean score for patient perception of CoC
of 7.1 and from carer/relative 8.1. Patients said they trusted their
doctor in 83.3% (Chao instrument). Opinion in relation to 
hospital care quality was: poor in 16.8%, regular in 12.5% 
and good/very good in 50% (Salmoni instrument). About social
capital: 91.6% trusted public institutions in their community and
in people living in the neighbourhood in 54.2%. Patients
received help to attend medical facilities in 4.2% from the neigh-
bour, 4.2% from a friend; patients helped the neighbour in
16.7% and a friend in 54.2%. CONCLUSIONS: Most of stroke
patients interviewed were satisﬁed with the quality of rehabili-
tation provided by the IMSS. CoC score from patient and carer
was acceptable and similar. Social capital level was also good.
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OBJECTIVES: This study assesses predictors of stroke recur-
rence in a Medicaid population, speciﬁcally examining persis-
tence on clopidogrel, warfarin and aspirin drug therapy.
METHODS: Medical and pharmacy claims for patients with a
diagnosis of stroke (ICD-9 Codes 430–438) were obtained from
Medicaid for the period of January 1, 2001–December 31, 2003.
Only patients with at least one month of follow up were
included. In order to obtain an incident cohort, patients who had
a stroke diagnosis between January 1, 2001–June 30, 2001 were
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excluded. Cox proportional hazard models were built to predict
the time dependent likelihood of no recurrence, as a function of
drug persistence, for patients who start on clopidogrel, warfarin
or aspirin, adjusting for blood pressure lowering and lipid low-
ering drugs taken after the ﬁrst stroke, hypertension, heart
disease, diabetes, race, gender, age and residence (urban or not).
RESULTS: In total, there were 925 patients, 36% older than 60,
58% African Americans, and 35% males. Patients who persist
on the ﬁrst drug taken post-stroke (HR = 1.29, p = 0.03, CI
1.02–1.63), start on clopidogrel (HR = 1.42, p = 0.006 CI
1.10–1.82) or take up to two (HR = 1.43, p = 0.001, CI
1.15–1.78) blood pressure lowering drugs post-stroke are sig-
niﬁcantly more likely to have no recurrence. Patients with a diag-
nosis of heart disease (HR = 0.81, p = 0.05, CI 0.66–0.99),
hypertension (HR = 0.64, p = 0.00, CI 0.51–0.79) or diabetes
(HR = 0.75, p = 0.006, CI 0.61–0.92) post-stroke are less likely
to have no recurrence, i.e. to stay in remission after the ﬁrst
stroke. CONCLUSIONS: Among Medicaid patients, persistence
on the ﬁrst drug taken after a stroke reduces the likelihood of
recurrence. Clopidogrel and the combination of up to two blood
pressure lowering drugs are associated with a higher likelihood
of no recurrence. However, heart disease, hypertension and dia-
betes decrease the likelihood of avoiding a second stroke. These
results may inform care management plans for Medicaid
patients.
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DISABILITY MEASURES IN STROKE: SCORE CONVERSION
BETWEEN THE BARTHEL INDEX AND THE MOTOR
COMPONENT OF FUNCTIONAL INDEPENDENCE MEASURE
FOR PRACTITIONER
Kwon S, Duncan PW
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OBJECTIVES: Disability presents a major economic and human-
istic burden among stroke survivors. To quantify disability in
patients, activities of daily living (ADLs) measures have been
used. The translation among measures, however, has not been
developed, leaving a signiﬁcant discontinuation of patient care
between facilities that use different measures. The purpose of 
this study is to develop a conversion system for two most widely
used ADL measures, the Motor component in Functional 
Independence Measure (M-FIM) and the Barthel Index (BI).
METHODS: We use Kansas City Stroke Study data. We stan-
dardized the scales of both instruments to 0–1 and rotated them
45 degrees in order to get a consistent conversion scheme regard-
less of the direction of the conversion (from BI to M-FIM or from
M-FIM to BI). We applied the censored heteroscedastic regres-
sion spline model using Monte Carlos Expectation and Condi-
tional Maximization (MCECM) algorithm, since the data is
censored in both boundaries (for M-FIM: 13–91, and BI: 0–100)
with ceiling and ﬂoor effects. RESULTS: Among 1676 records,
2.4% and 5.8% of M-FIM records, and 3.5% and 24% of BI
presented the lowest and highest scores respectively. Based on
our model, zero, 60, and 100 of BI scores are equivalent to 13
to 15, 59 to 62, and 88 to 91 of M-FIM. (Complete conversion
table will be provided in the presentation.) The two measures
were highly correlated (r = 0.9479, p < 0.0001), but the linear-
ity assumption was improper, particularly, for the higher score
range of the M-FIM and BI. CONCLUSIONS: For the contin-
uum of patient care, the conversion among scales is an impor-
tant issue. We developed a conversion scheme between two
widely used ADL measures, BI and M-FIM, based on their total
scores. Further research is planned to obtain a more robust and
precise conversion model addressing item level information.
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OBJECTIVES: We aimed to determine whether, and by how
much, stroke severity, as measured by the Modiﬁed Rankin Scale
(MRS) of disability, inﬂuences the duration of subsequent dis-
ability, and therefore the need for rehabilitation and nursing care.
METHODS: A total of 7599 patients were enrolled in a ran-
domised clinical trial (MATCH) of clopidogrel vs. aspirin +
clopidogrel after a transient ischaemic attack or ischaemic stroke
within 90 days (median 15 days). The two study arms were
pooled. The Modiﬁed Rankin Scale (MRS) was assessed at: base-
line (randomisation), months one, three, six, 12, 18 and follow-
ing a recurrent stroke. RESULTS: At baseline, 20.7% of 7599
patients were disabled (11.6% at MRS 3, 8.6% at MRS 4 and
0.5% at MRS 5). Median time to change from disabled state
(MRS 3, 4, or 5) to non-disabled state (MRS 0, 1, or 2) was
three-months for patients with moderate disability (MRS 3) and
18 months for patients with severe disability (MRS 4). For
patients with very severe disability (MRS 5), 80.7% remained
disabled at 18-months. Among the 804 patients who experienced
a recurrent ischaemic stroke during the study, 53.4% of patients
were disabled after the recurrent stroke (20.3% at MRS 3,
20.8% at MRS 4, and 12.3% for MRS 5). Median time to
change from disabled state to non-disabled state was six-months
for MRS 3 and more than 18-months for MRS 4. For MRS 5,
94.5% of patients still remained disabled. CONCLUSIONS:
More severe strokes and recurrent strokes cause longer-term dis-
ability. After a recurrent stroke, the median time to change from
a disabled to non-disabled state is six-months for patients with
moderate disability (MRS 3) and more than 18-months for
patients with severe disability (MRS 4). Almost all patients with
very severe disability (MRS 5), remain disabled and require per-
manent nursing care.
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ECONOMIC EVALUATION OF SIROLIMUS-ELUTING STENTS
IN JAPAN
Kobayashi M, Ikeda S
Keio University School of Medicine,Tokyo, Japan
OBJECTIVES: Percutaneous coronary intervention (PCI) using
a sirolimus-eluting stent (SES), coated with the immunosuppres-
sive agent sirolimus, dramatically reduces the risk of restenosis
compared to bare metal stent (BMS) implantation. However,
before SES can be widely adopted in clinical practice, it is essen-
tial to conduct an economic evaluation of this effective but
expensive device. Our study was undertaken to estimate the
three-year cumulative medical costs of stenting using SES com-
pared to BMS in the Japanese health care system. METHODS:
The data on clinical sequelae of stenting using BMS were derived
from our previous study, based on data collected from three
Japanese hospitals. We estimated that the probability of target-
lesion revascularization would be 0.15 times in SES implantation
compared to BMS implantation based on the recent meta-
analysis results (Babarille et al, 2004). The medical costs for pro-
cedures were obtained from published articles and were adjusted
to the January, 2005 level. Annual discount rate was set to 0.03.
Sensitivity analyses with different presumptions, including the
cost of intervention, the probability of target-lesion revascular-
